Sanofi R&D Belgium based in Ghent is as an end-to-end research and early development Center of Excellence and active in the discovery of NANOBODY® molecules, through the development of drugs up to their clinical proof-of-concept.
NANOBODY® molecules are proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. NANOBODY® technology is the next generation of antibody-derived biologics and have great potential. They are being developed for the treatment of a range of serious and life-threatening human diseases including hematology, inflammation, immune-oncology, oncology and rare diseases.
